MARKET OUTLOOKThe lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli Lilly…
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and…
MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…
Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key prostate cancer patient populations covering 171 countries and more than 99%…